Table 3.
Logistic regression analyses comparing baseline prevalence of T2DM in TGD cohort members and matched reference groups
| Analysis typea | T2DM cases | T2DM prevalenceb | vs reference CF | vs reference CM |
|---|---|---|---|---|
| at baseline | (95% CI) | OR (95% CI) | OR (95% CI) | |
| All TF participants | 175 | 61 (52.5-70.4) | 1.3 (1.1-1.5) | 0.9 (0.8-1.1) |
| TF participants on GAHT | 56 | 61 (46.6-78.7) | 1.0 (0.7-1.3) | 0.7 (0.5-1.0) |
| All TM participants | 77 | 36 (28.6-44.9) | 1.2 (0.9-1.5) | 1.1 (0.8-1.4) |
| TM participants on GAHT | 19 | 37 (22.7-57.8) | 1.1 (0.7-1.9) | 1.0 (0.6-1.6) |
CF, cisgender females; CI, confidence interval; CM, cisgender males; GAHT, gender-affirming hormone therapy; OR, odds ratio; T2DM, type 2 diabetes mellitus; TF, transfeminine; TM, transmasculine.
a All models adjusted for body mass index.
b Per 1000 participants.